studi
report
bacteri
lysat
bl
prophylact
effect
recurr
respiratori
tract
infect
rrti
howev
control
clinic
studi
procedur
evolv
substanti
sinc
perform
trial
use
updat
method
evalu
efficaci
lantigen
b
chemic
bl
doubl
blind
placebo
control
multicent
clinic
trial
primari
object
assess
capac
lantigen
b
significantli
reduc
total
number
infecti
episod
patient
rrti
secondari
aim
rrti
durat
frequenc
sever
acut
episod
use
drug
number
miss
workday
subgroup
allerg
patient
rrti
number
allerg
episod
ae
use
antiallerg
drug
also
evalu
one
hundr
sixti
patient
alloc
treat
group
tg
placebo
group
pg
enrol
lost
studi
femal
male
evalu
pg
episod
followup
tg
episod
p
similar
result
observ
allerg
patient
episod
pg
tg
respect
p
use
antibiot
reduc
mean
day
treatment
tg
pg
logist
regress
analysi
indic
estim
risk
need
antibiot
nsaid
reduc
respect
regard
number
ae
signific
differ
observ
two
group
bronchodil
antihistamin
local
corticosteroid
reduc
respect
tg
lantigen
b
significantli
reduc
number
infecti
episod
patient
rrti
find
suggest
first
line
use
drug
prophylaxi
infecti
episod
patient
studi
report
bacteri
lysat
bl
prophylact
effect
recurr
respiratori
tract
infect
rrti
howev
control
clinic
studi
procedur
evolv
substanti
sinc
perform
trial
use
updat
method
evalu
efficaci
lantigen
b
chemic
bl
doubl
blind
placebo
control
multicent
clinic
trial
primari
object
assess
capac
lantigen
b
significantli
reduc
total
number
infecti
episod
patient
rrti
secondari
aim
rrti
durat
frequenc
sever
acut
episod
use
drug
number
miss
workday
subgroup
allerg
patient
rrti
number
allerg
episod
ae
use
antiallerg
drug
also
evalu
one
hundr
sixti
patient
alloc
treat
group
tg
placebo
group
pg
enrol
lost
studi
femal
male
evalu
pg
episod
followup
tg
episod
p
similar
result
observ
allerg
patient
episod
pg
tg
respect
p
use
antibiot
reduc
mean
day
treatment
tg
pg
logist
regress
analysi
indic
estim
risk
need
antibiot
nsaid
reduc
respect
regard
number
ae
signific
differ
observ
two
group
bronchodil
antihistamin
local
corticosteroid
reduc
respect
tg
lantigen
b
significantli
reduc
number
infecti
episod
patient
rrti
find
suggest
first
line
use
drug
prophylaxi
infecti
episod
patient
author
publish
elsevi
bv
open
access
articl
cc
licens
http
recurr
respiratori
tract
infect
rrti
less
frequent
adult
children
frequenc
patient
affect
remain
signific
therapi
base
antiinflammatori
drug
antibiot
rare
infect
prophylaxi
provid
bacteri
lysat
bl
famili
biolog
drug
introduc
therapi
mani
decad
ago
last
year
mechan
action
elucid
sinc
first
vivo
studi
hypothes
clinic
effect
observ
relat
capac
bl
elicit
specif
immunerespons
bacteri
antigen
along
line
sinc
mid
specif
iga
direct
bacteri
antigen
observ
salivari
fluid
treat
patient
follow
oral
administr
bacteri
lysat
descript
tolllik
receptor
tlr
famili
function
within
larger
context
pattern
recognit
receptor
prr
system
explain
innat
immun
system
alert
presenc
differ
stimuli
mainli
repres
bacteri
deriv
structur
period
central
role
dendrit
cell
dc
gener
effici
immunerespons
describ
start
line
evid
differ
bacteri
lysat
shown
abl
induc
signific
activ
matur
dc
vitro
recent
use
specif
member
bacteri
lysat
famili
polyval
mechan
bacteri
lysat
pmbl
relev
effect
observ
b
cell
cell
nk
cell
effect
also
correl
clinic
result
bacteri
lysat
obtain
physic
chemic
lysi
former
gener
compos
fragment
bacteri
bodi
latter
may
constitut
either
low
molecular
weight
protein
mixtur
bacteri
bodi
solubl
protein
lantigen
b
belong
latter
famili
suspens
bacteri
antigen
obtain
streptococcu
pneumonia
type
streptococcu
pyogen
group
branhamella
catarrhali
staphylococcu
aureu
hemophilu
influenza
type
b
klebsiella
pneumonia
vivo
effect
lantigen
b
first
describ
mid
sinc
time
studi
perform
specif
drug
although
first
studi
consid
obsolet
procedur
point
view
drug
remain
pharmacolog
armamentarium
gener
practition
specialist
context
studi
even
total
line
modern
clinic
trial
practic
publish
demonstr
clinic
efficaci
lantigen
b
particular
main
effect
observ
reduct
infect
observ
period
inde
analyz
abovement
studi
calcul
mean
episodesyear
observ
treat
patient
vs
placebo
group
correspond
reduct
number
infecti
episod
addit
studi
reduct
cough
lost
day
antibiot
use
also
observ
note
one
nonposit
studi
common
cold
publish
other
demonstr
efficaci
treatment
studi
use
modern
effect
clinic
practic
tool
reevalu
efficaci
lantigen
b
doubl
blind
random
placebocontrol
clinic
trial
induc
signific
reduct
number
infecti
episod
unselect
real
lifelik
popul
patient
rrti
type
studi
need
verifi
previou
result
use
updat
methodolog
also
avail
drug
third
gener
antihistamin
local
corticosteroid
modern
bronchodil
recent
demonstr
deep
impact
manag
allerg
patient
repres
signific
fraction
patient
rrti
acut
episod
upper
respiratori
airway
identifi
continu
presenc
rhinorrhea
seromuc
purul
pharyng
couch
last
least
h
without
fever
acut
episod
lower
respiratori
airway
defin
continu
presenc
stridor
wheez
crackl
rhonchi
indraw
respiratori
frequenc
cyclesmin
cyanosi
last
least
h
without
fever
acut
episod
otiti
defin
continu
presenc
pain
erythema
reduct
loss
tympan
membran
mobil
final
acut
infecti
episod
defin
new
least
h
pass
complet
absenc
symptom
resolut
previou
episod
identif
infecti
event
base
patient
report
fever
cough
dyspnea
use
drug
well
doctor
report
visit
therapeut
indic
protocol
provid
infecti
episod
occur
patient
might
contact
primari
care
physician
studi
center
enrol
herhim
case
diagnosi
therapi
report
patient
diari
case
report
form
nation
multicent
longitudin
prospect
random
doubl
blind
versu
placebo
control
clinic
phase
iv
studi
conduct
two
parallel
group
observ
period
month
protocol
eudract
code
primari
goal
evalu
efficaci
lantigen
b
treatment
number
infecti
episod
ie
group
treat
patient
secondari
goal
total
number
day
ie
month
followup
b
frequenc
sever
episod
allergi
ae
particular
asthma
rhinoconjunct
c
diseas
free
period
evalu
time
occurr
ie
end
one
treatment
cycl
drug
consumpt
month
period
includ
antiinfecti
antiinflammatori
antiallerg
drug
e
enumer
day
absenc
commun
school
work
f
safeti
toler
treatment
studi
conduct
accord
good
clinic
practic
also
approv
ethic
committe
ec
univers
genova
aou
san
martino
refer
institut
princip
investig
ec
remain
center
also
approv
protocol
studi
recruit
start
septemb
finish
end
decemb
followup
finish
studi
close
septemb
clinic
statist
data
avail
decemb
studi
carri
differ
center
repres
differ
italian
climat
studi
enrol
men
woman
age
year
inclus
criteria
patient
complain
two
infect
upper
respiratori
year
preced
studi
possibl
associ
respiratori
allergi
b
absenc
type
malform
signific
diseas
ie
cancer
immunolog
disord
c
capac
understand
studi
collabor
investig
exclus
criteria
recurr
respiratori
infect
last
day
enrol
b
acut
diseas
either
infecti
infecti
requir
hospit
c
gastroesophag
reflux
cystic
fibrosi
defect
ciliar
diskynesi
e
chronic
system
diseas
f
bodi
mass
percentil
age
g
autoimmun
diseas
h
drug
immunoglobulin
immunostimul
antineoplast
drug
cytokin
interferon
interleukin
immunosuppressor
system
corticosteroid
known
allergi
intoler
studi
product
excipi
k
patient
could
contact
telephon
studi
l
patient
recruit
clinic
studi
last
month
enrol
studi
random
list
base
ranuni
random
number
gener
sa
softwar
sa
institut
cari
nc
usa
type
random
two
group
treat
group
receiv
lantigen
b
bruschettini
srl
oral
drop
lantigen
b
suspens
bacteri
antigen
obtain
pneumonia
type
pyogen
group
b
catarrhali
aureu
h
influenza
type
b
k
pneumonia
distil
water
ph
contain
undetect
dose
chlorhexidin
diacet
mgml
placebo
control
characterist
name
aspect
ph
chlorhexidin
bacteri
antigen
present
bottl
cycl
treatment
repres
total
drop
two
differ
daili
administr
morn
even
fast
schedul
follow
interv
week
anoth
week
treatment
observ
period
two
addit
treatment
schedul
interv
week
end
second
treatment
cycl
patient
followedup
anoth
week
tabl
show
treatment
schedul
period
studi
immunestimul
drug
cytokin
interferon
immunesuppressor
antineoplast
drug
allow
system
steroid
use
continu
week
also
allow
use
forbidden
drug
caus
exclus
patient
studi
drug
allow
record
patient
person
diari
three
visit
schedul
treatment
first
visit
includ
enrol
second
visit
begin
second
week
cycl
third
visit
end
second
followup
period
first
visit
patient
evalu
defin
whether
inclus
exclus
criteria
met
posit
case
patient
ask
enrol
clinic
trial
enrol
visit
patient
underw
physic
examin
evalu
vital
sign
evalu
life
style
clinic
histori
smoke
habit
enrol
patient
sign
inform
consent
includ
random
procedur
receiv
studi
drug
patient
train
use
drop
dispens
instruct
investig
regard
take
daili
treatment
accord
provid
schedul
final
patient
exhaust
instruct
compil
daili
diari
ask
record
relev
event
occur
thu
presenc
declin
patient
condit
symptom
record
intens
evalu
use
scale
absenc
presenc
sever
symptom
administ
drug
medic
visit
possibl
hospit
also
record
diari
patient
also
ask
care
record
use
studi
drug
accord
provid
schedul
also
requir
return
bottl
contain
box
investig
next
visit
second
visit
investig
record
advers
reaction
hospit
period
modif
life
style
work
school
habit
drug
use
particular
antibiot
antiinflammatori
drug
etc
visit
first
phase
diari
retir
infecti
allerg
episod
record
case
report
form
crf
remain
drug
also
retir
drug
second
cycl
given
togeth
second
part
diari
third
final
visit
end
second
period
observ
use
record
param
eter
second
visit
retir
remain
drug
diari
patient
allow
withdraw
treatment
reason
possibl
advers
reaction
use
drug
record
retir
patient
person
diari
retir
relev
inform
record
crf
complianc
treatment
evalu
compar
regist
dose
amount
remain
drug
bottl
patient
investig
ask
monitor
possibl
occurr
advers
reaction
ar
classifi
certain
like
possibl
unlik
unrel
evalu
accord
definit
protocol
ar
also
classifi
slight
interf
daili
activ
intermedi
ar
interf
day
activ
sever
ar
inhibit
daili
activ
patient
exclud
studi
presenc
sever
ar
incompat
continu
particip
studi
frequenc
viral
infect
gener
popul
period
studi
previou
year
evalu
result
molecular
biologybas
research
influenza
virus
parainfluenza
virus
bocavirus
coronavirus
rhinovirus
enterovirus
adenovirus
respiratori
syncyti
viru
record
frequenc
viral
infect
base
percentag
posit
sampl
describ
thu
increas
percentag
posit
sampl
consid
repres
increas
circul
pathogen
given
period
sampl
size
calcul
total
patient
patient
per
group
requir
recruit
consid
expect
drop
patient
enrol
intent
treat
itt
thu
total
patient
expect
evalu
primari
efficaci
analysi
base
itt
efficaci
treatment
two
group
evalu
analysi
covari
ancova
analysi
total
number
infect
episod
depend
variabl
treatment
group
factor
number
previou
year
infect
episod
covari
ancova
model
adjust
baselin
covari
perform
subgroup
analys
perform
complianc
rule
suggest
european
medicin
agenc
guidelin
investig
subgroup
confirmatori
clinic
trial
binari
variabl
measur
effect
treatment
secondari
object
analyz
test
final
logist
regress
multivari
analysi
use
evalu
probabl
use
drug
antibiot
nsaid
whole
popul
local
corticosteroid
antihistamin
drug
bronchodil
subset
allerg
patient
otiti
tonsil
sinus
pharyngotonsil
rhinopharyng
bronchiti
pneumonia
total
statist
carri
use
spss
data
extract
crf
total
patient
treat
group
placebo
group
enrol
age
placebo
group
mean
standard
deviat
age
treat
group
year
one
hundr
seventeen
patient
treat
placebo
group
complet
studi
fig
drop
observ
lantigen
b
group
patient
placebo
group
patient
patient
lost
inadequ
complianc
violat
protocol
seven
patient
three
advers
reaction
five
lost
followup
correspond
consent
withdraw
final
two
lost
reason
patient
complet
studi
gender
equilibr
placebo
male
femal
treat
group
respect
p
tabl
lane
relat
refer
period
show
clinic
characterist
patient
line
elig
criteria
number
patient
recruit
number
dropout
could
impact
power
studi
result
howev
differ
placebo
treatment
signific
efficaci
treatment
higher
could
expect
basi
publish
literatur
posthoc
power
studi
confirm
inde
sampl
size
group
power
detect
probabl
observ
lantigen
b
group
less
observ
placebo
group
wilcoxon
ranksum
test
two
side
signific
level
note
power
consid
accept
scientif
commun
clinic
studi
thu
origin
design
studi
power
suitabl
achiev
complet
statist
signific
even
presenc
conspicu
dropout
enrol
patient
primari
object
studi
reduct
number
ie
month
followup
period
whole
group
enrol
patient
mean
frequenc
ie
year
preced
studi
ci
frequenc
male
slightli
higher
femal
correspond
mean
ie
month
month
respect
distribut
ie
placebo
support
differ
nonparametr
analysi
number
infecti
episod
show
median
valu
treat
group
placebo
group
better
defin
result
differ
episod
singl
patient
also
evalu
frequenc
patient
etc
ie
analyz
fig
show
frequenc
ie
prestudi
popul
lantigen
b
treat
group
placebo
group
placebo
group
iepati
p
compar
activ
group
regard
diseas
suffer
patient
frequenc
pharyngotonsil
pt
rhinopharyng
rp
bronchiti
b
remain
otiti
tonsil
sinus
rare
pneumonia
treatment
lantigen
b
total
number
infect
significantli
reduc
state
rel
frequenc
differ
clinic
pictur
remain
virtual
unmodifi
pt
rp
b
other
slightli
reduc
tabl
subgroup
analysi
patient
suffer
respiratori
allergi
placebo
treat
group
accord
evid
collect
elig
visit
also
perform
patient
allerg
episod
studi
period
oculorhinit
asthma
note
frequenc
ie
patient
allergi
slightli
higher
durat
ie
two
group
differ
day
placebo
lantigen
b
group
statist
signific
achiev
f
p
interv
ie
evalu
end
first
second
treatment
cycl
first
interv
differ
number
event
eight
placebo
five
treat
group
well
mean
interv
day
signific
howev
cumul
hazard
suffer
ie
placebo
lantigen
b
group
similar
result
even
statist
signific
observ
second
interv
six
ei
placebo
two
lantigen
b
group
relev
cumul
hazard
develop
ie
second
interv
placebo
lantigen
b
group
concomit
drug
use
treat
control
group
also
evalu
logist
regress
analysi
three
famili
drug
use
antibiot
nsaid
evalu
whole
popul
antiallerg
drug
includ
bronchodil
local
corticosteroid
antihistamin
evalu
subset
allerg
patient
signific
differ
observ
treat
control
group
even
clear
trend
evid
inde
treat
patient
alway
treat
less
despit
logist
regress
analysi
demonstr
differ
signific
p
p
p
p
p
antibiot
nsaid
antihistamin
local
corticosteroid
bronchodil
respect
statist
show
probabl
exp
b
also
call
oddsratio
use
antibiot
reduc
exp
b
treat
patient
nsaid
exp
b
antiallerg
drug
exp
b
corticosteroid
exp
b
bronchodil
exp
b
treat
group
thu
logist
regress
show
drug
trend
toward
reduct
confirm
signific
reduct
number
ie
p
p
whole
group
subset
allerg
patient
final
group
mean
day
absenc
work
low
placebo
day
lantigen
b
p
regard
ar
record
lantigen
b
placebo
ar
describ
detail
tabl
briefli
ar
lantigen
b
group
occur
differ
patient
differ
patient
placebo
group
ar
could
relat
administr
lantigen
b
placebo
dri
burn
mouth
two
episod
one
patient
group
stomat
odinophagia
oropharynx
burn
five
episod
placebo
group
last
three
ar
requir
suspens
therapi
ar
includ
hypothyroid
distort
left
ankl
arthralgia
lung
cancer
headach
urinari
tract
infect
vagin
candidiasi
viral
gastroenter
oral
herp
hypertens
nausea
gastroenter
reflux
relat
treatment
lung
cancer
requir
suspens
drug
ar
also
classifi
accord
sever
need
therapi
interrupt
ti
placebo
group
ar
divid
slight
requir
ti
intermedi
requir
ti
sever
interrupt
lantigen
b
group
requir
ti
respect
studi
period
name
septemb
circul
respiratori
virus
qualit
quantit
term
larg
superimpos
previou
year
use
refer
interv
calcul
number
ie
patient
recruit
fig
show
result
survey
rsv
influenza
virus
clearli
present
decemberapril
interv
two
differ
period
virus
adenovirus
rhinovirus
detect
remain
period
report
efficaci
chemic
bacteri
lysat
lantigen
b
reduct
number
ie
patient
rrti
clearli
demonstr
use
rigor
scientif
clinic
approach
inde
phase
iv
studi
conduct
differ
center
use
doubl
blind
placebo
control
studi
protocol
author
awar
studi
effect
bacteri
lysat
conduct
past
use
control
clinic
trial
good
clinic
practic
gpc
train
hospit
studi
foreseen
number
patient
recruit
expect
lost
studi
howev
clinic
center
even
though
strongli
commit
abl
recruit
patient
lost
patient
could
evalu
end
studi
loss
onefourth
tabl
advers
reaction
placebo
group
patient
cohort
relev
phenomenon
despit
reduct
posthoc
analysi
show
number
evalu
patient
still
suffici
maintain
statist
relev
studi
thu
valid
observ
result
moreov
advers
reaction
record
well
caus
dropout
extrem
heterogen
virtual
unrel
treatment
signific
reduct
number
ie
observ
treat
group
averag
episod
month
studi
period
observ
lantigen
b
treat
patient
placebo
group
mean
episod
context
note
popul
recruit
averag
number
previou
ie
correspond
month
state
period
studi
mean
number
ie
placebo
group
month
femal
ie
male
ie
differ
may
differ
explan
differ
weather
epidem
condit
two
subsequ
year
differ
winter
spring
climat
warmer
temperatur
less
aggress
flu
viru
epidem
may
reduc
number
respiratori
tract
infect
allow
placebo
mimic
pharmacolog
posit
effect
moreov
certain
suscept
effect
placebo
evid
femal
male
certain
tendenc
increas
number
ie
group
describ
sever
condit
may
also
influenc
studi
result
regard
differ
period
epidemiolog
note
survey
viru
infect
studi
season
compar
previou
cold
season
show
virtual
ident
result
main
virus
influenza
rhinovirus
adenovirus
rsv
preval
two
period
therefor
find
support
hypothesi
differ
infecti
environ
caus
differ
number
respiratori
tract
infect
studi
popul
reduct
number
ie
placebo
group
may
depend
wellknown
bia
hawthorn
effect
phenomenon
origin
defin
industri
set
extend
realm
medic
research
suggest
subject
behavior
studi
result
may
alter
subject
awar
studi
receiv
addit
attent
also
note
recruit
base
number
respiratori
tract
infect
previou
year
even
gener
certain
tendenc
patient
involuntari
increas
report
number
infecti
episod
might
occur
fact
least
part
explain
differ
observ
howev
overcom
problem
doubl
blind
placebo
control
studi
like
present
one
mandatori
measur
differ
treatment
placebo
period
year
locat
context
find
neither
doctor
patient
realli
recogn
superior
activ
treatment
also
intrigu
cours
posit
effect
placebo
discuss
certain
role
importantli
differ
observ
homogen
distribut
placebo
treat
group
clearli
mean
posit
effect
administr
bacteri
lysat
could
observ
popul
level
less
evid
individu
level
addit
also
explain
medic
commun
sometim
skeptic
use
drug
inde
use
person
daili
experi
feel
difficult
establish
whether
famili
drug
activ
interest
inconclus
data
deriv
analysi
use
drug
two
group
statist
signific
differ
observ
placebo
treat
group
antibiot
nsaid
bronchodil
antihistamin
local
steroid
howev
clear
trend
observ
treat
group
use
drug
alway
reduc
group
regard
small
group
allerg
patient
first
observ
popul
rrti
patient
patient
allergi
symptom
repres
total
evid
treatment
lantigen
b
significantli
alter
number
allerg
episod
number
day
allergi
find
expect
even
strict
correl
allergi
symptom
respiratori
infecti
diseas
could
suggest
potenti
posit
effect
certain
effect
observ
trend
use
antiallergi
drug
inde
allerg
patient
logist
regress
show
probabl
use
drug
specif
allergi
reduc
critic
rais
studi
number
patient
recruit
even
statist
correct
larg
b
patient
recruit
follow
function
laboratori
test
perform
ie
advers
reaction
occur
c
concomit
diseas
potenti
mimick
symptom
respiratori
tract
unknown
primari
immun
defici
undiagnos
defect
howev
rare
studi
cohort
age
year
specif
consid
nonperfect
synchron
recruit
start
septemb
close
decemb
associ
followup
could
least
part
dilut
effect
typic
infect
winterspr
period
howev
strength
studi
sever
particular
rigor
random
homogen
distribut
abovement
bias
two
cohort
b
statist
analys
ancova
logist
regress
document
effect
lantigen
b
number
ie
also
identifi
clear
trend
toward
reduct
use
concomit
therapi
lantigen
b
treat
patient
c
real
lifelik
enrol
patient
state
heterogen
advers
reaction
relat
administr
drug
repres
popul
daili
access
offic
gener
practition
specialist
thu
observ
result
reliabl
conclus
administr
lantigen
b
evalu
doubl
blind
control
clinic
studi
result
signific
reduct
number
ie
treat
group
particular
frequenc
ie
reduc
popul
level
also
level
individu
number
episod
lower
treat
placebo
group
control
respiratori
tract
infect
least
famili
work
environ
result
reduc
spread
pathogen
reduc
use
drug
antibiot
evid
advantag
patient
commun
conclus
describ
result
togeth
signific
reduct
concomit
therapi
virtual
absenc
advers
reaction
indic
drug
may
use
effect
first
line
drug
prophylaxi
infecti
episod
patient
rrti
capac
control
respiratori
tract
infect
find
particularli
relev
period
global
increas
respiratori
infect
record
also
new
antibiot
avail
market
next
year
g
rinaldi
md
declar
fulltim
scientif
director
bruschettini
srl
g
melioli
md
advisor
bruschettini
srl
research
develop
author
report
conflict
interest
work
